ArticleScientific reports2025
Fibrinogen alpha and beta chains as non-invasive predictors of hepatocellular carcinoma progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MALDI-MSI Profiling of Effusion Cytology Cell Blocks Distinguishes High-Grade Serous Ovarian Carcinoma from Benign Effusions.Cancers · 2026Article
- Single-Cell Transcriptomic Profiling Reveals Immunometabolic Reprogramming and Cell-Cell Communication in the Tumor Microenvironment of Human Hepatocellular Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) poses a significant global health burden due to its high incidence and mortality rates. Early diagnosis is crucial for improving patient outcomes; however, current diagnostic methods, such as the measurement of α-fetoprotein (AFP) levels, have notable limitations. Our study aimed to explore non-invasive markers with superior diagnostic efficacy for HCC. Our findings revealed a significant downregulation of FGA, FGB, and FGG in HCC, with lower expression levels strongly associated with reduced overall survival and disease-free survival rates. Notably, the diagnostic accuracies of FGA and FGB in detecting HCC, particularly in its early stages, surpassed that of AFP. ELISA results further confirmed the reduced serum levels of these proteins in HCC patients. In addition, a negative correlation was observed between fibrinogen expression and the abundance of myeloid-derived suppressor cells in HCC. FGA and FGB emerge as promising non-invasive biomarkers for HCC, offering improved diagnostic accuracy compared to AFP. Their consistent downregulation across different stages of HCC and their linkage to the tumor microenvironment underscore their potential role in HCC pathogenesis. These insights warrant further investigation and may contribute to the development of more effective diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.